FDA issues first draft guidance on psychedelic research
Mental Health Weekly – June 30, 2023
Source: OpenAlex
Summary
The Food and Drug Administration recently made history by issuing its first-ever draft guidance for conducting clinical trials with psychedelic drugs. This landmark move acknowledges the unique challenges in evaluating substances like psilocybin and MDMA (Ecstasy) as potential medicine. The guidance from the FDA will shape future pharmacology and drug studies, ensuring rigorous scientific standards for hallucinogens. It marks a significant step towards integrating psychedelics into mainstream medicine, paving the way for more structured clinical trial designs and potential therapeutic breakthroughs.
Abstract
Observing that designing clinical studies to evaluate the safety and effectiveness of psychedelic substances presents a number of unique challenges that require careful consideration to the industry, the U.S. Food and Drug Administration (FDA) last month issued, for the first time, draft guidance for conducting clinical trials with psychedelic drugs such as psilocybin and MDMA (ecstasy).